<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS97943</article-id>
<article-id pub-id-type="doi">10.1101/2020.10.05.327577</article-id>
<article-id pub-id-type="archive">PPR222570</article-id>
<article-version article-version-type="publisher-id">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Molecular basis for <italic>B. pertussis</italic> interference with complement, coagulation, fibrinolytic and contact activation systems: The cryo-EM structure of the Vag8-C1 inhibitor complex</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Dhillon</surname>
<given-names>Arun</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Deme</surname>
<given-names>Justin C.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Furlong</surname>
<given-names>Emily</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Roem</surname>
<given-names>Dorina</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jongerius</surname>
<given-names>Ilse</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Johnson</surname>
<given-names>Steven</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lea</surname>
<given-names>Susan M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Sir William Dunn School of Pathology, South Parks Road, Oxford OX1 3RE, UK</aff>
<aff id="A2">
<label>2</label>Central Oxford Structural Molecular Imaging Centre, South Parks Road, Oxford, OX1 3RE, UK</aff>
<aff id="A3">
<label>3</label>Sanquin Research, Department of Immunopathology, and Landsteiner Laboratory, Amsterdam University Medical Centre, Amsterdam Infection and Immunity Institute, Amsterdam, the Netherlands</aff>
<aff id="A4">
<label>4</label>Department of Pediatric Immunology, Rheumatology, and Infectious Diseases, Emma Children's Hospital, Amsterdam University Medical Centre, Amsterdam, the Netherlands</aff>
<author-notes>
<corresp id="CR1">
<label>*</label>to whom correspondence should be addressed, <email>steven.johnson@path.ox.ac.uk</email>, <email>susan.lea@path.ox.ac.uk</email>
</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>13</day>
<month>10</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="preprint">
<day>07</day>
<month>10</month>
<year>2020</year>
</pub-date>
<permissions>
<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0 International license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P1">Complement, contact activation, coagulation, and fibrinolysis are serum protein cascades that need strict regulation to maintain human health. Serum glycoprotein, C1-inhibitor (C1-INH) is a key regulator (inhibitor) of serine proteases of all the above-mentioned pathways. Recently, an autotransporter protein, Virulence Associated Gene 8 (Vag8) produced by the whopping cough causing pathogen, <italic>Bordetella pertussis</italic> has been shown to bind and interfere with C1INH function. Here we present the structure of Vag8: C1-INH complex determined using cryo-electron microscopy at 3.6 Å resolution. The structure shows a unique mechanism of C1-INH inhibition not employed by other pathogens where Vag8 sequesters the Reactive Centre Loop of the C1-INH preventing its interaction with the target proteases.</p>
<sec id="S1">
<title>Importance</title>
<p id="P2">The structure 105 kDa protein complex is one of the smallest to be determined using cryo-electron microscopy at high resolution. The mechanism of disrupting C1-INH revealed by the structure is crucial to understand how pathogens by producing a single virulence factor can disturb several homeostasis pathways. Virulence mechanisms such as the one described here assume more importance given the emerging evidence about dysregulation of contact activation, coagulation and fibrinolysis leading to COVID-19 pneumonia.</p>
</sec>
</abstract>
<kwd-group>
<kwd>
<italic>Bordetella pertussis</italic>
</kwd>
<kwd>immune evasion</kwd>
<kwd>complement system</kwd>
<kwd>SERPIN</kwd>
<kwd>autotransporters</kwd>
<kwd>C1-INH</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="S2" sec-type="intro">
<title>Introduction</title>
<p id="P3">Protein cascades coordinate key processes for health within human serum, in particular immune and inflammatory responses (complement and contact activation) and control of clotting (contact activation, coagulation and fibrinolysis) (<xref ref-type="bibr" rid="R1">1</xref>–<xref ref-type="bibr" rid="R3">3</xref>). Although independent processes, coordination between the pathways occurs by shared regulation, particularly by C1inhibtor (C1-INH) (<xref ref-type="bibr" rid="R4">4</xref>). C1-INH inhibits serine proteases involved in activation and control of these systems by formation of protease-C1-INH complexes such that the level of these complexes is directly proportional to the level of <italic>in vivo</italic> activation of all four systems (<xref ref-type="bibr" rid="R5">5</xref>). C1INH is established as a key regulator of complement via inhibition of the activation proteases C1r, C1s, MASP-1 and MASP-2 and is the dominant inhibitor of plasma kallikrein (contact activation system), coagulation factors XIIa and XIa and thrombin (<xref ref-type="bibr" rid="R6">6</xref>–<xref ref-type="bibr" rid="R10">10</xref>). The mode of inhibition of these proteases involves interaction between the Reactive Centre Loop (RCL) of the C-terminal Serpin domain of C1-INH to form a covalently linked acyl-enzyme complex that distorts the enzyme active site and is irreversibly bound (<xref ref-type="bibr" rid="R11">11</xref>–<xref ref-type="bibr" rid="R13">13</xref>). Additionally, C1-INH has been implicated in regulation of fibrinolysis via action against tissue-type plasminogen activator (tPA) and plasmin – although study of this is complicated by the fact that both these enzymes will also cleave C1-INH (<xref ref-type="bibr" rid="R14">14</xref>, <xref ref-type="bibr" rid="R15">15</xref>).</p>
<p id="P4">Whooping cough (pertussis) is an infectious disease of the respiratory system caused by the Gram-negative bacterium <italic>Bordetella pertussis</italic> (<xref ref-type="bibr" rid="R16">16</xref>). <italic>B. pertussis</italic> employs a range of virulence factors to colonise the human host and evade immune responses (<xref ref-type="bibr" rid="R17">17</xref>). Some of these factors e.g. Virulence associate gene 8 (Vag8), <italic>Bordetella</italic> Resistance to Killing A (BrkA), Filamentous hemagglutinin (FHA) and B. pertussis autotransporter protein C (BapC) have been implicated in evasion of the complement system (<xref ref-type="bibr" rid="R18">18</xref>–<xref ref-type="bibr" rid="R21">21</xref>). While the mechanisms of action of BrkA, BapC, FHA are still unclear, Vag8, a 95 kDa auto-transporter protein was recently shown to interfere with the complement and contact systems by binding to C1-INH leading to bacterial complement evasion (<xref ref-type="bibr" rid="R22">22</xref>, <xref ref-type="bibr" rid="R23">23</xref>). Auto-transporters represent the type V bacterial secretion system and possess a C-terminal membrane embedded β-barrel domain that facilitates the translocation of the N-terminal passenger domain, responsible for effector functions, across the outer membrane (<xref ref-type="bibr" rid="R24">24</xref>). In case of Vag8 the cleaved N-terminal domain has been detected in bacterial culture supernatant in addition to the full length Vag8 being presented on outer membrane vesicles (OMVs), and on the cell surface (<xref ref-type="bibr" rid="R22">22</xref>). Deletion of the gene encoding Vag8 predisposes <italic>B. pertussis</italic> to complement mediated killing (<xref ref-type="bibr" rid="R18">18</xref>, <xref ref-type="bibr" rid="R22">22</xref>).</p>
<p id="P5">Although C1-INH is an inhibitor of complement activation, targeting C1-INH activity is used as a strategy for complement evasion by a range of different pathogens. <italic>Streptococcus pyogenes,</italic> and <italic>Legionella pneumophila</italic> use enzymes, SpeB and ChiA respectively, to cleave C1-INH (<xref ref-type="bibr" rid="R25">25</xref>, <xref ref-type="bibr" rid="R26">26</xref>), while <italic>Plasmodium falciparum, Borrelia recurrentis and Salmonella typhimurium</italic> depend on <italic>Pf</italic>MSP3.1, CihC, and lipopolysaccharide (<xref ref-type="bibr" rid="R27">27</xref>–<xref ref-type="bibr" rid="R29">29</xref>), respectively to capture C1-INH on the cell surface. A hybrid of the above two strategies of C1-INH targeting has been proposed to be used by <italic>E. coli O157:H7</italic> involving capture of C1-INH on the cell surface followed by an enzymatic cleavage (<xref ref-type="bibr" rid="R30">30</xref>). Whilst targeting an inhibitor to the pathogen surface is a self-evident way of enhancing immune evasion, the utility of destruction of C1INH is less obvious but occurs due to the fact that removal of C1-INH from serum leads to rapid, catastrophic activation of complement, leading to depletion of activity and so, perversely, less complement attack on the pathogen (<xref ref-type="bibr" rid="R22">22</xref>).</p>
<p id="P6">Globally, pertussis is responsible for a large number of infant deaths, especially in low income countries and is a financial burden even in developed economies (<xref ref-type="bibr" rid="R31">31</xref>, <xref ref-type="bibr" rid="R32">32</xref>). Despite extensive vaccination programs <italic>B. pertussis</italic> infections are on the rise again (<xref ref-type="bibr" rid="R33">33</xref>). Reasons to explain the rising infections have been contentious and include waning of immunity generated by acellular pertussis vaccines, and evolution of more pathogenic strains (<xref ref-type="bibr" rid="R34">34</xref>–<xref ref-type="bibr" rid="R37">37</xref>) therefore, a molecular understanding of the mode of action of <italic>B. pertussis</italic> virulence factors such as Vag8 is desirable. More broadly, with evidence mounting that activation of coagulation and excessive cytokine release are key drivers of COVID-19 pneumonia and mortality with contact activation appearing particularly important in driving pathologic upregulation of inflammatory mediators and coagulation, interest in pathogenic mechanisms acting on these systems is further increased (<xref ref-type="bibr" rid="R38">38</xref>–<xref ref-type="bibr" rid="R41">41</xref>).</p>
<p id="P7">To that end, we have determined the structure of the Vag8 passenger domain in complex with the C1-INH Serpin domain using single particle cryo-electron (cryo-EM) microscopy to 3.6 Å resolution. The Cryo-EM structure of this complex reveals that Vag8 non-covalently sequesters the reactive centre loop (RCL) of C1-INH in the groove of the elongated passenger domain so preventing C1-INH/protease interactions and regulation. Thus <italic>B. pertussis</italic> overrides complement regulatory control by a unique mechanism not previously seen in other pathogens. Sequestration of C1-INH in this manner not only leads to complement evasion but also promotes kallikrein activation, leading to increased levels of the vasoactive bradykinin, increased fibrinolysis, and coagulation. Thus <italic>B. pertussis</italic> widely perturbs serum activities across a broad spectrum by production of a single protein molecule.</p>
</sec>
<sec id="S3" sec-type="results">
<title>Results</title>
<p id="P8">To better understand how <italic>B. pertussis</italic> subverts C1-INH function we heterologously expressed and purified both the passenger domain of Vag8 and the Serpin domain of C1-INH (<xref ref-type="fig" rid="F1">Figure 1a, b</xref>). When mixed at an approximately equimolar ratio the proteins formed a complex that could be separated from a small amount of residual isolated C1-INH by size-exclusion chromatography (<xref ref-type="fig" rid="F1">Figure 1a, b</xref>). This Vag8:C1-INH complex was then concentrated to 0.5 mg/ml and applied to Quantifoil R1.2/1.3 carbon-coated grids before blotting using a Mark IV Vitrobot and plunge freezing in liquid ethane. Single particle cryoEM data were collected using a Titan Krios at 300kV equipped with a Gatan BioQuantum and K3 detector as described in the methods. The small size of the complex (~100 kDa) meant that individual particles were difficult to discern at the micrograph level (<xref ref-type="fig" rid="F1">Figure 1c</xref>), however manual picking of ~1000 particles followed by 2D classification generated 2D averages that were used for automated picking of more than 40,000 movies, collected from three grids (<xref ref-type="fig" rid="F1">Figure 1d</xref>). Data were processed as shown in the workflow (<xref ref-type="fig" rid="F1">Figure 1d</xref>) using both SIMPLE3.0 (<xref ref-type="bibr" rid="R42">42</xref>) and RELION3.1 (<xref ref-type="bibr" rid="R43">43</xref>) to yield a final volume based on 687,883 particles with an estimated resolution (by gold-standard FSC, 0.143 criterion) of 3.6 Å (<xref ref-type="fig" rid="F1">Figure 1e</xref>). Calculation of a local resolution filtered volume (<xref ref-type="fig" rid="F1">Figure 1f</xref>; RELION 3.1, (<xref ref-type="bibr" rid="R43">43</xref>)) demonstrates that the core of Vag8 and size of interaction with C1-INH is well defined, with a resolution estimate of 3.5Å despite the small size of this complex placing it amongst the ten smallest structures determined to date using this method (<xref ref-type="bibr" rid="R44">44</xref>).</p>
<p id="P9">A <italic>de novo</italic> model was built manually using program COOT (<xref ref-type="bibr" rid="R45">45</xref>) for the region 54-481 of Vag8. Although residual density could be seen in the volume both N- and C-terminal to this region (<xref ref-type="fig" rid="F2">Figure 2a</xref>), it was not possible to build an atomic model for residues 40-53 and 482-610. The model of the active form of the C1-INH Serpin domain (<xref ref-type="bibr" rid="R46">46</xref>) was placed and remodelled to fit the volume, with the only major changes in conformation being within the RCL which is seen to be sequestered within the cleft of the Vag8 beta-barrel fold. <xref ref-type="fig" rid="F2">Figure 2b</xref> shows the quality of the volume around key-side chains within the binding site. Following further cycles of manual rebuilding and real-space refinement in PHENIX (<xref ref-type="bibr" rid="R47">47</xref>) lead to the generation of the model presented in <xref ref-type="fig" rid="F2">Figure 2</xref> and described in <xref ref-type="table" rid="T1">Table 1</xref>.</p>
<p id="P10">The model for the complex reveals that C1-INH associates with the cleft within the Vag8 passenger domain beta-barrel, with two contact sites (<xref ref-type="fig" rid="F2">Figure 2c</xref>). The first involves contacts between two loops at the base of the C1-INH Serpin domain (around residues 317 and 362) and one of the longer loops incorporated in the Vag8 beta barrel (residues 407-410) (<xref ref-type="fig" rid="F2">Figure 2d</xref>). This is a fairly small contact area burying approximately 100 Å<sup>2</sup> on each protein. The other point of contact is a much more significant interaction which buries the side chains of the majority of the RCL residues between 461 and 474 within the Vag8 beta-barrel cleft burying ~600 Å<sup>2</sup> on both components (<xref ref-type="fig" rid="F2">Figure 2e</xref>).</p>
<p id="P11">To further probe the interactions seen in the complex we designed single and multiple point mutations in Vag8 to test their effect on complex formation. Mutant forms of Vag8 were expressed and purified then mixed with the C1-INH Serpin domain and complex formation was assayed by size-exclusion chromatography (<xref ref-type="fig" rid="F3">Figure 3a</xref>, <xref ref-type="table" rid="T2">Table 2</xref>). With the exception of a mutation designed to sterically block binding of the RCL loop in the cleft by replacement of a small alanine side chain with a very large arginine side chain (A231R; <xref ref-type="fig" rid="F3">Figure 3</xref>, Supplementary Table 1), mutation of multiple residues within the cleft to alanine was required to prevent formation of the complex emphasising the extended nature of the interaction site (<xref ref-type="fig" rid="F2">Figures 2</xref>, <xref ref-type="fig" rid="F3">3</xref>).</p>
</sec>
<sec id="S4" sec-type="discussion">
<title>Discussion</title>
<p id="P12">
<italic>B. pertussis</italic> targets regulation of immune, inflammatory and clotting processes by scavenging C1-INH using the passenger domain of Vag8. Our structure reveals that formation of this complex directly impacts on the physiological systems by masking the RCL required for C1INH to fulfil its inhibitory activities within the bacterial protein. Unlike the native function of C1-INH, which results in formation of a covalent link between the RCL and the target, the inhibitor complex buries the RCL loop within the cleft of the bacterial protein via non-covalent interactions. Formation of a stable complex involving the RCL loop sterically occludes C1INH interactions with its physiological partners.</p>
<p id="P13">
<italic>B. pertussis</italic> is not the only organism that acts on these systems via scavenging C1-INH and it remains to be seen if other organisms use similar structural strategies to achieve inhibition.</p>
</sec>
<sec id="S5" sec-type="materials | methods">
<title>Materials and Methods</title>
<sec id="S6">
<title>Expression and purification of Vag8</title>
<p id="P14">Cloning of Vag8 passenger domain (residues 40-610) into a modified pRSETb plasmid has been reported previously (<xref ref-type="bibr" rid="R22">22</xref>). The recombinant plasmid was transformed into <italic>Escherichia coli</italic> C41 (DE3) cells which were then plated on LB-agar plates supplemented with 50μg/ml ampicillin. Protein production was carried by growing <italic>E. coli</italic> C41 (DE3) cells expressing Vag8pd in LB medium supplemented with 50μg/ml ampicillin at 37°C and 180 rpm until A600 reached 0.5-0.6. At this point, the culture was induced with 1 mM Isopropyl β-D-1thiogalactopyranoside (IPTG) and further grown for 20 h at 24°C and 180 rpm. Cells were harvested by centrifugation at 5000 <italic>g</italic> for 10 min at 4°C. The cell pellet was resuspended in buffer A (50 mM Tris-HCl pH 8.0, 20 mM imidazole and 500 mM NaCl containing DNAase I and lysozyme). The cells were lysed using a Emulsiflex C5 homogeniser (Avestin) and the lysate cleared by centrifugation at 18000 <italic>g</italic>, 4°C for 45 min. The filtered supernatant was loaded onto a Ni-affinity chromatography column pre-equilibrated with buffer B (50 mM Tris-HCl pH 8.0, 20 mM imidazole and 500 mM NaCl). The Vag8 was eluted with a linear gradient of imidazole on an FPLC system (ÄKTA pure, GE Healthcare) using buffer B and buffer C (50 mM Tris-HCl pH 8.0, 500 mM imidazole and 500 mM NaCl). The eluted protein was dialysed overnight into buffer D (50 mM Tris-HCl pH 8.0 and 30 mM NaCl). The dialysed protein was subject to anion exchange chromatography and eluted by a linear gradient of NaCl using buffer D and buffer E (50 mM Tris-HCl pH 8.0, 1 M NaCl). Purified Vag8 was concentrated and the buffer was exchanged to buffer F (50 mM Tris-HCl pH 8.0, 150 mM NaCl) by ultrafiltration (Amicon Ultra, Merck-Millipore).</p>
</sec>
<sec id="S7">
<title>Site-directed mutagenesis of Vag8</title>
<p id="P15">Single mutations in Vag8 (H209A, Y234A, E237A, and W285A) were introduced using Q5 Site-directed mutagenesis (NEB). The Vag8 quadruple mutant (H209A Y234A E237A W285A) was produced by Gibson Assembly of overlapping fragments containing the desired mutations using NEBuilder HiFi Master Mix (NEB). Purification of Vag8 mutants was done as described above for wild type Vag8.</p>
</sec>
<sec id="S8">
<title>Expression and purification of C1-INH</title>
<p id="P16">A synthesised nucleotide fragment (codon optimised for <italic>Saccharomyces cerevisiae</italic>) encoding C1-INH amino acid residues 98-500 with Kozak and BiP signal sequence at 5′ end (GeneArt, ThermoScientific) was cloned using Gibson assembly (New England Biolabs) into pExpreS2-1 (ExpreS<sup>2</sup>ion Biotechnologies) plasmid, for protein production in <italic>Drosophila</italic> S2 cells, such that the mature recombinant protein had a His<sub>6</sub> -tag followed by a 3C protease cleavage site at the N terminus. The recombinant plasmid was transfected into S2 cells following manufacturer's protocol (ExpreS<sup>2</sup>ion Biotechnologies). Briefly, the recombinant plasmid was transfected into S2 cells and a stable cell line was selected over a period of four weeks while culturing the cells in EX-CELL420 medium (Sigma-Aldrich) supplemented with 10% (v/v) Fetal Bovine Serum (FBS) and 4 mg/ml zeocin. The stable cell line was maintained in EX-CELL420 medium supplemented with 10% (v/v) FBS, penicillin-streptomycin and amphotericin B, and cultured at 25°C, 110 rpm. For protein purification the stable cell line was split to a final cell density of 8 x 10<sup>6</sup> cells /ml and cultured in EX-CELL420 medium, supplemented with penicillin-streptomycin and amphotericin B only, at 25°C, 110 rpm. The culture was centrifuged at 4500 <italic>g</italic>, 4°C for 30 min to collect the supernatant containing the recombinant protein four days after the split. The supernatant was filtered and incubated with His-tag purification resin (Roche) overnight at 4°C while mixing gently. The supernatant was then passed through a low pressure gravity flow column to collect the resin, which was then washed with buffer F. The protein was eluted using buffer G (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 500 mM imidazole) followed by dialysis into buffer D. The dialysed protein was further purified using a MonoQ 10/30GL anion exchange chromatography column (GE Healthcare) by a linear gradient of NaCl with buffer D and buffer E. Purified C-INH protein was concentrated and the buffer exchanged to buffer F, 50 mM Tris-HCl pH 8.0, 150 mM NaCl by ultrafiltration (Amicon Ultra, Merck-Millipore).</p>
</sec>
<sec id="S9">
<title>Preparation of C1-INH and Vag8 complex</title>
<p id="P17">The Vag8:C1-INH complex was prepared <italic>in vitro</italic> by incubating C1-INH in ~1.5 molar excess with Vag8 at room temperature for 10 min followed by purification using size exclusion chromatography on a S200pg 16/600 column (GE Healthcare). The eluted fractions were analysed by SDS-PAGE followed by ultrafiltration to concentrate the protein complex.</p>
</sec>
<sec id="S10">
<title>Size exclusion chromatography to assay the binding of Vag8 mutants to C1-INH</title>
<p id="P18">A 100 μL mixture of C1-INH (20 mM) and Vag8 WT or mutant (10 mM) was prepared at room temperature and injected onto a S200 Increase 10/300GL column pre-equilibrated with 50 Mm Tris-HCl 150 mM NaCl pH 8.0. The samples were eluted at 0.4 mL/min and 0.5 mL fractions were collected.</p>
</sec>
<sec id="S11">
<title>Preparation of Cryo-EM grids</title>
<p id="P19">Four microliters of purified Vag8:C1-INH complex (0.5 mg/ml) was adsorbed to glow-discharged holey carbon-coated grids (Quantifoil 300 mesh, Au R1.2/1.3) for 10 s. Grids were then blotted for 3 s at 100% humidity at 8°C and frozen in liquid ethane using a Vitrobot Mark IV (FEI).</p>
</sec>
<sec id="S12">
<title>Cryo-EM data collection, processing and analysis</title>
<p id="P20">Data were collected in counted super-resolution mode on a Titan Krios G3 (FEI) operating at 300 kV with a BioQuantum imaging filter (Gatan) and K3 direct detection camera (Gatan) using either a) a physical pixel size of 1.068 Å, a dose rate of 15 e−/pix/s, and an exposure of 4.23 s, corresponding to a total dose of 55.6 e−/Å<sup>2</sup> or b) physical pixel size of 0.832 Å, a dose rate of 13.9 e−/pix/s, and an exposure of 2.97 s, corresponding to a total dose of 59.6 e−/Å<sup>2</sup>. All movies were collected over 40 fractions.</p>
<p id="P21">Motion correction, dose weighting, CTF estimation, particle picking and extraction were performed in streaming mode during collection using SIMPLE3.0 (<xref ref-type="bibr" rid="R42">42</xref>) as was 2D classification (<xref ref-type="bibr" rid="R42">42</xref>). <italic>Ab intio</italic> models were created in SIMPLE3.0 using particles selected from the chunks 1 &amp; 2 further processing was performed in RELION 3.1 (<xref ref-type="bibr" rid="R43">43</xref>). The full workflow is described in <xref ref-type="fig" rid="F1">Figure 1</xref> but briefly, each data set underwent an initial round of 3D classification before 3D autorefine steps, beamtilt refinement, Bayesian polishing and further rounds of 3D classification (<xref ref-type="bibr" rid="R43">43</xref>). Chunks of data were combined as described in <xref ref-type="fig" rid="F1">Figure 1</xref> with the final volume calculated from 6 87,883 particles in C1. The resolution of the final volume is estimated as 3.6 based on FSC=0.143 criterion with the Local Resolution volume (calculated in RELION3.1 (<xref ref-type="bibr" rid="R43">43</xref>)) demonstrating that much of the core of the complex is at a resolution of 3.5 or better.</p>
</sec>
</sec>
</body>
<back>
<ack id="S13">
<title>Acknowledgements</title>
<p>We thank the staff of the Central Oxford Structural Microscopy and Imaging Centre, Adam Costin and Errin Johnson and other members of the Lea group for assistance with various stages of the project. This work was funded by grants from the Wellcome Trust #219477, #209194 and #100298 and the Medical Research Council #S007474</p>
</ack>
<sec id="S14">
<title>Data availability</title>
<p id="P22">Coordinates and Volumes have been deposited in the PDB and EMDB respectively with accession codes 7KAV and 11814</p>
</sec>
<fn-group>
<fn id="FN1" fn-type="con">
<p id="P23">
<bold>Author Contributions</bold>
</p>
<p id="P24">AD cloned, expressed and purified complexes, performed binding studies. JCD prepared grids and collected single particle cryo EM data. EF screened cryo EM grids. DR cloned initial constructs. IJ, SJ &amp; SML conceived study. AD, SJ &amp; SML analysed data and wrote first draft of manuscript. SML processed cryoEM data and built models. All authors commented on final drafts of manuscript.</p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dunkelberger</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>W-C</given-names>
</name>
</person-group>
<article-title>Complement and its role in innate and adaptive immune responses</article-title>
<source>Cell Res</source>
<year>2010</year>
<volume>20</volume>
<fpage>34</fpage>
<lpage>50</lpage>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weidmann</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Heikaus</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Naudin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schlüter</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Renné</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>The plasma contact system, a protease cascade at the nexus of inflammation, coagulation and immunity</article-title>
<source>Biochim Biophys Acta - Mol Cell Res. Elsevier BV</source>
<year>2017</year>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chapin</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Hajjar</surname>
<given-names>KA</given-names>
</name>
</person-group>
<article-title>Fibrinolysis and the control of blood coagulation</article-title>
<source>Blood Rev</source>
<year>2015</year>
<volume>29</volume>
<fpage>17</fpage>
<lpage>24</lpage>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davis</surname>
<given-names>AE</given-names>
<suffix>3rd</suffix>
</name>
<name>
<surname>Mejia</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Biological activities of C1 inhibitor</article-title>
<source>Mol Immunol</source>
<year>2008</year>
<volume>45</volume>
<fpage>4057</fpage>
<lpage>4063</lpage>
<comment>2008/07/31</comment>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kajdácsi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Jandrasics</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Veszeli</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Makó</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Koncz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gulyás</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Köhalmi</surname>
<given-names>KV</given-names>
</name>
<name>
<surname>Temesszentandrási</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cervenak</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gál</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dobó</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Patterns of C1-Inhibitor/Plasma Serine Protease Complexes in Healthy Humans and in Hereditary Angioedema Patients</article-title>
<source>Front Immunol</source>
<year>2020</year>
<volume>11</volume>
<fpage>794</fpage>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sim</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Reboul</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Arlaud</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Villiers</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Colomb</surname>
<given-names>MG</given-names>
</name>
</person-group>
<article-title>Interaction of 125I-labelled complement subcomponents C-1r and C-1s with protease inhibitors in plasma</article-title>
<source>FEBS Lett</source>
<year>1979</year>
<volume>97</volume>
<fpage>111</fpage>
<lpage>115</lpage>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gigli</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Mason</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Colman</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Austen</surname>
<given-names>KF</given-names>
</name>
</person-group>
<article-title>Interaction of Plasma Kallikrein with the C1 Inhibitor</article-title>
<source>J Immunol</source>
<year>1970</year>
<volume>104</volume>
<fpage>574</fpage>
<lpage>581</lpage>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schreiber</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Austen</surname>
<given-names>KF</given-names>
</name>
</person-group>
<article-title>Inhibition by CaINH of Hageman Factor Fragment Activation of Coagulation, Fibrinolysis, and Kinin Generation</article-title>
<source>J Clin Invest</source>
<year>1973</year>
<volume>52</volume>
<fpage>1402</fpage>
<lpage>1409</lpage>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wuillemin</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Minnema</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Meijers</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Roem</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Eerenberg</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nuijens</surname>
<given-names>J</given-names>
</name>
<name>
<surname>ten Cate</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hack</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor</article-title>
<source>Blood</source>
<year>1995</year>
<volume>85</volume>
<fpage>1517</fpage>
<lpage>1526</lpage>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Nostrand</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>McKay</surname>
<given-names>LD</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Cunningham</surname>
<given-names>DD</given-names>
</name>
</person-group>
<article-title>Functional and structural similarities between protease nexin I and C1 inhibitor</article-title>
<source>J Biol Chem</source>
<year>1988</year>
<volume>263</volume>
<fpage>3979</fpage>
<lpage>83</lpage>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bock</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Skriver</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Thøgersen</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Wiman</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Donaldson</surname>
<given-names>VH</given-names>
</name>
<name>
<surname>Eddy</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Marrinan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Radziejewska</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Shows</surname>
<given-names>TB</given-names>
</name>
<etal/>
</person-group>
<article-title>Human C1* Inhibitor: Primary Structure, cDNA Cloning, and Chromosomal Localization</article-title>
<source>Biochemistry</source>
<year>1986</year>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beinrohr</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Harmat</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Dobó</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lörincz</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Gál</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Závodszky</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>C1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and conformational disease</article-title>
<source>J Biol Chem</source>
<year>2007</year>
<volume>282</volume>
<fpage>21100</fpage>
<lpage>21109</lpage>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huntington</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Read</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Carrell</surname>
<given-names>RW</given-names>
</name>
</person-group>
<article-title>Structure of a serpin-protease complex shows inhibition by deformation</article-title>
<source>Nature</source>
<year>2000</year>
<volume>407</volume>
<fpage>923</fpage>
<lpage>926</lpage>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thorsen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Philips</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Isolation of tissue-type plasminogen activator-inhibitor complexes from human plasmaEvidence for a rapid plasminogen activator inhibitor</article-title>
<source>Biochim Biophys Acta - Gen Subj</source>
<year>1984</year>
<volume>802</volume>
<fpage>111</fpage>
<lpage>118</lpage>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ratnoff</surname>
<given-names>OD</given-names>
</name>
<name>
<surname>Pensky</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ogston</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Naff</surname>
<given-names>GB</given-names>
</name>
</person-group>
<article-title>The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C'1r subcomponent of the first component of complement by serum C'1 esterase inhibitor</article-title>
<source>J Exp Med</source>
<year>1969</year>
<volume>129</volume>
<fpage>315</fpage>
<lpage>31</lpage>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kilgore</surname>
<given-names>PE</given-names>
</name>
<name>
<surname>Salim</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Zervos</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>H-J</given-names>
</name>
</person-group>
<article-title>Pertussis: Microbiology, Disease, Treatment, and Prevention</article-title>
<source>Clin Microbiol Rev</source>
<year>2016</year>
<volume>29</volume>
<fpage>449</fpage>
<lpage>486</lpage>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Melvin</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Scheller</surname>
<given-names>EV</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Cotter</surname>
<given-names>PA</given-names>
</name>
</person-group>
<article-title>Bordetella pertussis pathogenesis: current and future challenges</article-title>
<source>Nat Rev Microbiol</source>
<year>2014</year>
<volume>12</volume>
<fpage>274</fpage>
<lpage>288</lpage>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marr</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Fernandez</surname>
<given-names>RC</given-names>
</name>
</person-group>
<article-title>Bordetella pertussis autotransporter Vag8 binds human C1 esterase inhibitor and confers serum resistance</article-title>
<source>PLoS One</source>
<year>2011</year>
<volume>6</volume>
<fpage>e20585</fpage>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barnes</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>AA</given-names>
</name>
</person-group>
<article-title>BrkA protein of Bordetella pertussis inhibits the classical pathway of complement after C1 deposition</article-title>
<source>Infect Immun</source>
<year>2001</year>
<volume>69</volume>
<fpage>3067</fpage>
<lpage>3072</lpage>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berggård</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Johnsson</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Mooi</surname>
<given-names>FR</given-names>
</name>
<name>
<surname>Lindahl</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Bordetella pertussis binds the human complement regulator C4BP: role of filamentous hemagglutinin</article-title>
<source>Infect Immun</source>
<year>1997</year>
<volume>65</volume>
<fpage>3638</fpage>
<lpage>3643</lpage>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noofeli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bokhari</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Blackburn</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Coote</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Parton</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>BapC autotransporter protein is a virulence determinant of Bordetella pertussis</article-title>
<source>Microb Pathog</source>
<year>2011</year>
<volume>51</volume>
<fpage>169</fpage>
<lpage>177</lpage>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hovingh</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>van den Broek</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kuipers</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Pinelli</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rooijakkers</surname>
<given-names>SHM</given-names>
</name>
<name>
<surname>Jongerius</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Acquisition of C1 inhibitor by Bordetella pertussis virulence associated gene 8 results in C2 and C4 consumption away from the bacterial surface</article-title>
<source>PLOS Pathog</source>
<year>2017</year>
<volume>13</volume>
<fpage>e1006531</fpage>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hovingh</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>de Maat</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cloherty</surname>
<given-names>APM</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pinelli</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Maas</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Jongerius</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Virulence associated gene 8 of Bordetella pertussis enhances contact system activity by inhibiting the regulatory function of complement regulator C1 inhibitor</article-title>
<source>Front Immunol</source>
<year>2018</year>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bernstein</surname>
<given-names>HD</given-names>
</name>
</person-group>
<article-title>Type V Secretion: the Autotransporter and Two-Partner Secretion Pathways</article-title>
<source>EcoSal Plus</source>
<year>2010</year>
<volume>4</volume>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Honda-Ogawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ogawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Terao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Sumitomo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nakata</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ikebe</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Maeda</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kawabata</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Cysteine proteinase from Streptococcus pyogenes enables evasion of innate immunity via degradation of complement factors</article-title>
<source>J Biol Chem</source>
<year>2013</year>
<volume>288</volume>
<fpage>15854</fpage>
<lpage>15864</lpage>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rehman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Grigoryeva</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Richardson</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Corsini</surname>
<given-names>P</given-names>
</name>
<name>
<surname>White</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Portlock</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Dorgan</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zanjani</surname>
<given-names>ZS</given-names>
</name>
<name>
<surname>Fornili</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cianciotto</surname>
<given-names>NP</given-names>
</name>
<etal/>
</person-group>
<article-title>Structure and functional analysis of the Legionella pneumophila chitinase ChiA reveals a novel mechanism of metal-dependent mucin degradation</article-title>
<source>PLOS Pathog</source>
<year>2020</year>
<volume>16</volume>
<fpage>e1008342</fpage>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kennedy</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Wijeyewickrema</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Huglo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pike</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cowman</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Tham</surname>
<given-names>W-H</given-names>
</name>
</person-group>
<article-title>Recruitment of Human C1 Esterase Inhibitor Controls Complement Activation on Blood Stage Plasmodium falciparum Merozoites</article-title>
<source>J Immunol</source>
<year>2017</year>
<volume>198</volume>
<fpage>4728</fpage>
<lpage>4737</lpage>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grosskinsky</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schott</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Brenner</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cutler</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Wallich</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Human complement regulators C4b-binding protein and C1 esterase inhibitor interact with a novel outer surface protein of Borrelia recurrentis</article-title>
<source>PLoS Negl Trop Dis</source>
<year>2010</year>
<volume>4</volume>
<fpage>e698</fpage>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cramer</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Scafidi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>AE</given-names>
<suffix>3rd</suffix>
</name>
</person-group>
<article-title>N-linked glycosylation at Asn3 and the positively charged residues within the amino-terminal domain of the c1 inhibitor are required for interaction of the C1 Inhibitor with Salmonella enterica serovar typhimurium lipopolysaccharide and lipid A</article-title>
<source>Infect Immun</source>
<year>2005</year>
<volume>73</volume>
<fpage>4478</fpage>
<lpage>4487</lpage>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lathem</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Bergsbaken</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Welch</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Potentiation of C1 esterase inhibitor by StcE, a metalloprotease secreted by Escherichia coli O157:H7</article-title>
<source>J Exp Med</source>
<year>2004</year>
<volume>199</volume>
<fpage>1077</fpage>
<lpage>1087</lpage>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yeung</surname>
<given-names>KHT</given-names>
</name>
<name>
<surname>Duclos</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>EAS</given-names>
</name>
<name>
<surname>Hutubessy</surname>
<given-names>RCW</given-names>
</name>
</person-group>
<article-title>An update of the global burden of pertussis in children younger than 5 years: a modelling study</article-title>
<source>Lancet Infect Dis</source>
<year>2017</year>
<volume>17</volume>
<fpage>974</fpage>
<lpage>980</lpage>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Masseria</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Krishnarajah</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>LK</given-names>
</name>
<name>
<surname>Buikema</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>TQ</given-names>
</name>
</person-group>
<article-title>Incidence and Burden of Pertussis Among Infants Less Than 1 Year of Age</article-title>
<source>Pediatr Infect Dis J</source>
<year>2017</year>
<volume>36</volume>
<fpage>e54</fpage>
<lpage>e61</lpage>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jackson</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Rohani</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Perplexities of pertussis: recent global epidemiological trends and their potential causes</article-title>
<source>Epidemiol Infect</source>
<year>2014</year>
<volume>142</volume>
<fpage>672</fpage>
<lpage>684</lpage>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Domenech de Cellès</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Magpantay</surname>
<given-names>FMG</given-names>
</name>
<name>
<surname>King</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Rohani</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>The impact of past vaccination coverage and immunity on pertussis resurgence</article-title>
<source>Sci Transl Med</source>
<year>2018</year>
<volume>10</volume>
<comment>eaaj1748</comment>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Winter</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>NP</given-names>
</name>
<name>
<surname>Ackley</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cherry</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Comment on “The impact of past vaccination coverage and immunity on pertussis resurgence.”</article-title>
<source>Sci Transl Med</source>
<year>2018</year>
<volume>10</volume>
<comment>eaau0548</comment>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klein</surname>
<given-names>NP</given-names>
</name>
<name>
<surname>Bartlett</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rowhani-Rahbar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fireman</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Baxter</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Waning protection after fifth dose of acellular pertussis vaccine in children</article-title>
<source>N Engl J Med</source>
<year>2012</year>
<volume>367</volume>
<fpage>1012</fpage>
<lpage>1019</lpage>
</element-citation>
</ref>
<ref id="R37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Sen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Weigand</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Skoff</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Cunningham</surname>
<given-names>VA</given-names>
</name>
<name>
<surname>Halse</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Tondella</surname>
<given-names>ML</given-names>
</name>
</person-group>
<article-title>
<italic>Bordetella pertussis</italic> Strain Lacking Pertactin and Pertussis Toxin</article-title>
<source>Emerg Infect Dis</source>
<year>2016</year>
<volume>22</volume>
<fpage>319</fpage>
<lpage>322</lpage>
</element-citation>
</ref>
<ref id="R38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia</article-title>
<source>J Thromb Haemost</source>
<year>2020</year>
<volume>18</volume>
<fpage>844</fpage>
<lpage>847</lpage>
</element-citation>
</ref>
<ref id="R39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Merad</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages</article-title>
<source>Nat Rev Immunol</source>
<year>2020</year>
<volume>20</volume>
<fpage>355</fpage>
<lpage>362</lpage>
</element-citation>
</ref>
<ref id="R40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ragab</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Salah Eldin</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Taeimah</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Khattab</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Salem</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>The COVID-19 Cytokine Storm; What We Know So Far</article-title>
<source>Front Immunol</source>
<year>2020</year>
<volume>11</volume>
<fpage>1446</fpage>
</element-citation>
</ref>
<ref id="R41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shatzel</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>DeLoughery</surname>
<given-names>EP</given-names>
</name>
<name>
<surname>Lorentz</surname>
<given-names>CU</given-names>
</name>
<name>
<surname>Tucker</surname>
<given-names>EI</given-names>
</name>
<name>
<surname>Aslan</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Hinds</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Gailani</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Weitz</surname>
<given-names>JI</given-names>
</name>
<name>
<surname>McCarty</surname>
<given-names>OJT</given-names>
</name>
<name>
<surname>Gruber</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>The contact activation system as a potential therapeutic target in patients with COVID-19</article-title>
<source>Res Pract Thromb Haemost</source>
<year>2020</year>
<volume>4</volume>
<fpage>500</fpage>
<lpage>505</lpage>
</element-citation>
</ref>
<ref id="R42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reboul</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Eager</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Elmlund</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Elmlund</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Single-particle cryo-EM-Improved ab initio 3D reconstruction with SIMPLE/PRIME</article-title>
<source>Protein Sci</source>
<year>2018</year>
<volume>27</volume>
<fpage>51</fpage>
<lpage>61</lpage>
</element-citation>
</ref>
<ref id="R43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zivanov</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nakane</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Scheres</surname>
<given-names>SHW</given-names>
</name>
</person-group>
<article-title>Estimation of high-order aberrations and anisotropic magnification from cryo-EM data sets in RELION -3.1</article-title>
<source>IUCrJ</source>
<year>2020</year>
<volume>7</volume>
<fpage>253</fpage>
<lpage>267</lpage>
</element-citation>
</ref>
<ref id="R44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lander</surname>
<given-names>GC</given-names>
</name>
</person-group>
<article-title>How low can we go? Structure determination of small biological complexes using single-particle cryo-EM</article-title>
<source>Curr Opin Struct Biol</source>
<year>2020</year>
<volume>64</volume>
<fpage>9</fpage>
<lpage>16</lpage>
</element-citation>
</ref>
<ref id="R45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Emsley</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lohkamp</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>WG</given-names>
</name>
<name>
<surname>Cowtan</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Features and development of Coot</article-title>
<source>Acta Crystallogr Sect D Biol Crystallogr</source>
<year>2010</year>
<volume>66</volume>
<fpage>486</fpage>
<lpage>501</lpage>
</element-citation>
</ref>
<ref id="R46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dijk</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Holkers</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Voskamp</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Giannetti</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Waterreus</surname>
<given-names>W-J</given-names>
</name>
<name>
<surname>van Veen</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Pannu</surname>
<given-names>NS</given-names>
</name>
</person-group>
<article-title>How Dextran Sulfate Affects C1-inhibitor Activity: A Model for Polysaccharide Potentiation</article-title>
<source>Structure</source>
<year>2016</year>
<volume>24</volume>
<fpage>2182</fpage>
<lpage>2189</lpage>
</element-citation>
</ref>
<ref id="R47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Afonine</surname>
<given-names>PV</given-names>
</name>
<name>
<surname>Poon</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Read</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Sobolev</surname>
<given-names>OV</given-names>
</name>
<name>
<surname>Terwilliger</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Urzhumtsev</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>PD</given-names>
</name>
</person-group>
<article-title>Real-space refinement in PHENIX for cryo-EM and crystallography</article-title>
<source>Acta Crystallogr Sect D, Struct Biol</source>
<year>2018</year>
<volume>74</volume>
<fpage>531</fpage>
<lpage>544</lpage>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<title>Determination of the single particle CryoEM structure of the Vag8:C1-INH complex at 3.6 Å</title>
<p>(<bold>a</bold>) Size exclusion chromatography analysis shows that Vag8 binds C1-INH to form a complex (purple). 100μl of an approximately 1:2 molar ratio of Vag8: C1-INH were mixed and purified using a S200 increase chromatography column. A, B and C denote the locations at which Vag8:C1-INH complex, Vag8 and C1-INH respectively elute. (<bold>b</bold>) Fractions under peaks A &amp; C from Vag8:C1-INH purification when run on 15% (w/v) SDS-PAGE gel confirm that the peak at location A contains Vag8 bound to C1-INH while unbound C1-INH elutes in peak C. (<bold>c</bold>) A representative micrograph of Vag8:C1-INH complex on a carbon-coated grid. Scale bar 200 Å (<bold>d</bold>) cryo-EM data of Vag8:C1-INH complex were collected and initially processed as 3 different chunks (Chunk 1, 2 and 3) and combined at later stages during processing using SIMPLE 3.0 and RELION 3.1. Masked 3D classification of chunk 2 data was done using the initial volume and mask from chunk 1. Subsequently, selected particles from chunk 1 and 2 were combined and masked 3D classification was performed. Selected particles from this data set were combined with selected particles from chunk 3 data obtained after masked 3D auto-refine and masked 3D classification. This final combined data set was then auto-refined and postprocessed in RELION 3.1 resulting in 3.6 Å volume. Scale bar on 2D averages is 50 Å (<bold>e</bold>) Gold-standard Fourier Shell Corelation curves of Vga8:C1-INH complex volumes postprocessed in RELION 3.1. Curves: red, phase-randomized; green, unmasked; blue, masked; black, corrected (<bold>f</bold>) Volume coloured by estimated Local resolution (Å).</p>
</caption>
<graphic xlink:href="EMS97943-f001"/>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<title>Structure of Vag8:C1-INH complex</title>
<p>(<bold>a</bold>) Views of the model of Vag8:C-INH in the experimental volume. Both proteins are shown in a cartoon representation, Vag8 coloured from blue at the N-terminus to red at the C-terminus and C1-INH coloured blue. Volume is contoured at 3s. Figure drawn using PyMOL (The PyMOL Molecular Graphics System, Version 2.0 Schrodinger, LLC) (<bold>b</bold>) shows a closeup of the central portion of the C-INH RCL in the Vag8 cleft with key residue interactions highlighted. (<bold>c</bold>) an overview of the complex with the two points of contact boxed (<bold>d</bold>) shows a closeup of the interactions in the smaller contact site boxed and labelled (i) in panel (<bold>c</bold>), (<bold>e</bold>) shows two views from the top and end of the complex of the larger interaction site boxed and labelled (ii) in panel (<bold>c</bold>).</p>
</caption>
<graphic xlink:href="EMS97943-f002"/>
</fig>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<title>Mutation of residues within the interface abolishes complex formation</title>
<p>(<bold>a</bold>) 100μl of an approximately 1:2 molar ratio of Vag8 : C1-INH were mixed and purified using a S200 increase chromatography column. A, B and C denote the locations at which Vag8:C1-INH complex, Vag8 and C1-INH respectively elute. Vag8H209A (dashed black line) is one of the mutations that make up the Vag8QUAD set and is still capable of forming a complex with C1-INH (as are the other mutations that form the Vag8<sub>QUAD</sub> set in isolation, data not shown), whereas both Vag8<sub>QUAD</sub> (green) and Vag8<sub>A231R</sub> (orange) do not form any complex with C1-INH under these conditions and the two mixed components elute independently in peaks B and C (<bold>b-d</bold>) Views of the Vag8:C1-INH complex with Vag8 shown as grey cartoon, C1-INH as blue cartoon, residues mutated shown as space-filling spheres with carbons coloured to reflect colour scheme of panel (<bold>a</bold>). The C1-INH RCL loop is coloured dark red and the main chain atoms shown as spheres in panel (<bold>b</bold>). Panels (<bold>b-d</bold>) drawn using PyMOL (The PyMOL Molecular Graphics System, Version 2.0 Schrodinger, LLC)</p>
</caption>
<graphic xlink:href="EMS97943-f003"/>
</fig>
<table-wrap id="T1" position="float" orientation="portrait">
<label>Table 1</label>
<caption>
<title>Structure solution and model quality</title>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top"/>
<th colspan="3" valign="top" align="center">
<italic>Human C1inhibitor complex with B. pertussis Vag 8</italic> (EMD-11814) (PDB 7AKV)</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="4" valign="top" align="left">
<bold>Data collection and processing</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">Magnification</td>
<td valign="top" align="center">81,000</td>
<td align="center" valign="top" rowspan="4"/>
<td valign="top" align="center">105,000</td>
</tr>
<tr>
<td valign="top" align="left">Voltage (kV)</td>
<td valign="top" align="center">300</td>
<td valign="top" align="center">300</td>
</tr>
<tr>
<td valign="top" align="left">Electron exposure (e–/Å2)</td>
<td valign="top" align="center">55.6</td>
<td valign="top" align="center">59.6</td>
</tr>
<tr>
<td valign="top" align="left">Defocus range (μm)</td>
<td valign="top" align="center">0.5-2.5</td>
<td valign="top" align="center">0.5-2.5</td>
</tr>
<tr>
<td valign="top" align="left">Pixel size (Å)</td>
<td valign="top" align="center">1.068 physical pixel (0.534 super resolution)</td>
<td valign="top" align="center"/>
<td valign="top" align="center">0.832 physical pixel (0.416 super resolution)</td>
</tr>
<tr>
<td valign="top" align="left">Symmetry imposed</td>
<td valign="top" align="center">C1</td>
<td valign="top" align="center"/>
<td valign="top" align="center">C1</td>
</tr>
<tr>
<td valign="top" align="left">Initial particle images (no.)</td>
<td align="center" valign="top" rowspan="6">5,842,723</td>
<td valign="top" align="center"/>
<td align="center" valign="top" rowspan="6">11,418,635</td>
</tr>
<tr>
<td valign="top" align="left">Final combined particle images on 0.832 Å</td>
<td valign="top" align="center">687,883</td>
</tr>
<tr>
<td valign="top" align="left">pixel scale (no.)</td>
<td valign="top" align="center">3.6</td>
</tr>
<tr>
<td valign="top" align="left">Map resolution (Å)</td>
<td valign="top" align="center">0.143</td>
</tr>
<tr>
<td valign="top" align="left">   FSC threshold</td>
<td valign="top" align="center">3.5-5.4</td>
</tr>
<tr>
<td valign="top" align="left">Map resolution range (Å)</td>
<td valign="top" align="center"/>
</tr>
<tr>
<td colspan="4" valign="top" align="left">
<bold>Refinement</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">Initial model used (PDB code)</td>
<td align="left" valign="top" colspan="3">C1-INH - 5du3; Vag8 - none</td>
</tr>
<tr>
<td valign="top" align="left">Model resolution (Å)</td>
<td colspan="3" valign="top" align="left">3.6</td>
</tr>
<tr>
<td valign="top" align="left">FSC threshold</td>
<td colspan="3" valign="top" align="left">0.143</td>
</tr>
<tr>
<td valign="top" align="left">Model resolution range (Å)</td>
<td colspan="3" valign="top" align="left">3.5-5.4</td>
</tr>
<tr>
<td valign="top" align="left">Map sharpening B factor (Å<sup>2</sup>)</td>
<td colspan="3" valign="top" align="left">-107</td>
</tr>
<tr>
<td colspan="4" valign="top" align="left">Model composition</td>
</tr>
<tr>
<td valign="top" align="left">    Non-hydrogen atoms</td>
<td valign="top" align="left">6203</td>
<td align="center" valign="top" rowspan="3"/>
<td align="center" valign="top" rowspan="3"/>
</tr>
<tr>
<td valign="top" align="left">    Protein residues</td>
<td valign="top" align="left">799</td>
</tr>
<tr>
<td valign="top" align="left">    Ligands</td>
<td valign="top" align="left">0</td>
</tr>
<tr>
<td colspan="4" valign="top" align="left">B factors (Å<sup>2</sup>)</td>
</tr>
<tr>
<td valign="top" align="left">    Protein</td>
<td valign="top" align="left">49</td>
<td align="center" valign="top" rowspan="2"/>
<td align="center" valign="top" rowspan="2"/>
</tr>
<tr>
<td valign="top" align="left">    Ligand</td>
<td valign="top" align="left">NA</td>
</tr>
<tr>
<td colspan="4" valign="top" align="left">R.M.S. Deviations</td>
</tr>
<tr>
<td valign="top" align="left">    Bond lengths (Å)</td>
<td valign="top" align="left">0.004</td>
<td align="center" valign="top" rowspan="2"/>
<td align="center" valign="top" rowspan="2"/>
</tr>
<tr>
<td valign="top" align="left">    Bond angles (°)</td>
<td valign="top" align="left">0.631</td>
</tr>
<tr>
<td colspan="4" valign="top" align="left">Validation</td>
</tr>
<tr>
<td valign="top" align="left">    MolProbity score</td>
<td valign="top" align="left">3.05</td>
<td align="center" valign="top" rowspan="3"/>
<td align="center" valign="top" rowspan="3"/>
</tr>
<tr>
<td valign="top" align="left">    Clashscore</td>
<td valign="top" align="left">74.5</td>
</tr>
<tr>
<td valign="top" align="left">    Poor rotamers (%)</td>
<td valign="top" align="left">0.16</td>
</tr>
<tr>
<td colspan="4" valign="top" align="left">Ramachandran plot</td>
</tr>
<tr>
<td valign="top" align="left">    Favored (%)</td>
<td valign="top" align="left">82.2</td>
<td align="center" valign="top" rowspan="3"/>
<td align="center" valign="top" rowspan="3"/>
</tr>
<tr>
<td valign="top" align="left">    Allowed (%)</td>
<td valign="top" align="left">17.8</td>
</tr>
<tr>
<td valign="top" align="left">    Disallowed (%)</td>
<td valign="top" align="left">0.0</td>
</tr>
<tr>
<td colspan="4" valign="top" align="left">Map to Model FSC</td>
</tr>
<tr>
<td valign="top" align="left">    0.5 criterion (Å)</td>
<td valign="top" align="left">3.8</td>
<td align="center" valign="top" rowspan="2"/>
<td align="center" valign="top" rowspan="2"/>
</tr>
<tr>
<td valign="top" align="left">    0.143 criterion (Å)</td>
<td valign="top" align="left">2.9</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T2" position="float" orientation="portrait">
<label>Table 2</label>
<caption>
<p>Binding analysis of Vag8 mutants by size exclusion chromatography. ‘+' indicates Vag8:C1-INH complex peak seen, ‘-' indicates proteins elute separately and no complex peak observed.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="top" align="center">Vag8 Mutation</th>
<th valign="top" align="center">Phenotype/C1-INH binding activity</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="center">H209A</td>
<td valign="top" align="center">+</td>
</tr>
<tr>
<td valign="top" align="center">A231R</td>
<td valign="top" align="center">-</td>
</tr>
<tr>
<td valign="top" align="center">Y234A</td>
<td valign="top" align="center">+</td>
</tr>
<tr>
<td valign="top" align="center">E237A</td>
<td valign="top" align="center">+</td>
</tr>
<tr>
<td valign="top" align="center">W285A</td>
<td valign="top" align="center">+</td>
</tr>
<tr>
<td valign="top" align="center">H209A Y234A E237A W285A</td>
<td valign="top" align="center">-</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
